Potential Role of Glucose Transporter-1 Expression in Gastric Cancer: A Meta-Analysis and Systematic Review

Overview

Journal Iran J Public Health

Date 2021 Mar 12

PMID 33708725

Authors

Jianxin Tao

Ye Zhang

Tong Wang

Affiliations

Soon will be listed here.

Abstract

Background: Glucose transporter-1 (GLUT-1) has been differentially expressed in various malignancies including gastric cancer (GC). Several previous meta-analyses of GLUT-1 have some significant limitations, such as researching the association between GLUT-1 and various cancer types with no specificity, not studying clinicopathological parameters with GLUT-1, existing conspicuous heterogeneity and so forth. Therefore, we performed a meta-analysis to evaluate the association between GLUT-1 expression and survival of gastric cancer patients, as well as clinicopathological characteristics.

Methods: We systematically searched PubMed, Embase, Web of Science and China National Knowledge Infrastructure for relevant studies in accordance with the applicable criteria up to Aug 2017. Hazard ratios (HRs) and odds ratios (ORs) with their 95% confidence intervals (CIs) were used as the effective measures.

Results: A total of 13 studies involving 1972 patients were included in this meta-analysis. The results demonstrated that there was a significant association between GLUT-1 expression and overall survival (OS) (HR=1.45, 95% CI=1.13-1.87) or disease-free survival (DFS) (HR=2.18, 95% CI=1.46-3.25). Moreover, GLUT-1 expression was significantly correlated with worse tumor nodes metastases (TNM) stage (OR=0.34, 95% CI=0.28-0.43), presence of lymph node metastasis (OR=2.88, 95% CI=1.34-6.19), intestinal type of Lauren classification (OR=3.84, 95% CI=2.57-5.74) and invasion of serosa (OR=0.25, 95% CI=0.18-0.35).

Conclusion: Our meta-analysis showed that GLUT-1 was significantly correlated with poor OS and DFS in gastric cancer. Additionally, GLUT-1 was also a potential prognostic indicator of aggressive clinicopathological parameters in gastric cancer.

References

Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu M . Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000; 60(6):1541-5. View

Barron C, Bilan P, Tsakiridis T, Tsiani E . Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment. Metabolism. 2016; 65(2):124-39. DOI: 10.1016/j.metabol.2015.10.007. View

Alakus H, Batur M, Schmidt M, Drebber U, Baldus S, Vallbohmer D . Variable 18F-fluorodeoxyglucose uptake in gastric cancer is associated with different levels of GLUT-1 expression. Nucl Med Commun. 2010; 31(6):532-8. DOI: 10.1097/MNM.0b013e32833823ac. View

Shen Y, Arbman G, Olsson B, Sun X . Overexpression of GLUT1 in colorectal cancer is independently associated with poor prognosis. Int J Biol Markers. 2011; 26(3):166-72. DOI: 10.5301/JBM.2011.8550. View

Sharen G, Peng Y, Cheng H, Liu Y, Shi Y, Zhao J . Prognostic value of GLUT-1 expression in pancreatic cancer: results from 538 patients. Oncotarget. 2017; 8(12):19760-19767. PMC: 5386719. DOI: 10.18632/oncotarget.15035. View

Ramani P, Headford A, May M . GLUT1 protein expression correlates with unfavourable histologic category and high risk in patients with neuroblastic tumours. Virchows Arch. 2013; 462(2):203-9. DOI: 10.1007/s00428-012-1370-4. View

Yu M, Zhou Q, Zhou Y, Fu Z, Tan L, Ye X . Metabolic phenotypes in pancreatic cancer. PLoS One. 2015; 10(2):e0115153. PMC: 4342019. DOI: 10.1371/journal.pone.0115153. View

Wei B, Chen L, Li J . [Expression of glucose transporter 1 in gastric carcinoma and metastatic lymph nodes and its association with prognosis]. Zhonghua Wei Chang Wai Ke Za Zhi. 2009; 12(3):277-80. View

Yang J, Wen J, Tian T, Lu Z, Wang Y, Wang Z . GLUT-1 overexpression as an unfavorable prognostic biomarker in patients with colorectal cancer. Oncotarget. 2017; 8(7):11788-11796. PMC: 5355304. DOI: 10.18632/oncotarget.14352. View

10.

Yu M, Yongzhi H, Chen S, Luo X, Lin Y, Zhou Y . The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis. Oncotarget. 2017; 8(26):43356-43367. PMC: 5522151. DOI: 10.18632/oncotarget.17445. View

11.

Chen X, Lu P, Zhou S, Zhang L, Zhao J, Tang J . Predictive value of glucose transporter-1 and glucose transporter-3 for survival of cancer patients: A meta-analysis. Oncotarget. 2017; 8(8):13206-13213. PMC: 5355089. DOI: 10.18632/oncotarget.14570. View

12.

Zhao F, Keating A . Functional properties and genomics of glucose transporters. Curr Genomics. 2008; 8(2):113-28. PMC: 2435356. DOI: 10.2174/138920207780368187. View

13.

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

14.

Semenza G . Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3(10):721-32. DOI: 10.1038/nrc1187. View

15.

Zhang W, Chen C, Zhou Z, Gao S, Tee T, Yang L . Hypoxia-inducible factor-1 alpha Correlates with Tumor-Associated Macrophages Infiltration, Influences Survival of Gastric Cancer Patients. J Cancer. 2017; 8(10):1818-1825. PMC: 5556645. DOI: 10.7150/jca.19057. View

16.

Ajani J . Gastroesophageal cancers: progress and problems. J Natl Compr Canc Netw. 2008; 6(9):813-4. View

17.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

18.

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

19.

Liberti M, Locasale J . The Warburg Effect: How Does it Benefit Cancer Cells?. Trends Biochem Sci. 2016; 41(3):211-218. PMC: 4783224. DOI: 10.1016/j.tibs.2015.12.001. View

20.

DeBerardinis R, Lum J, Hatzivassiliou G, Thompson C . The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008; 7(1):11-20. DOI: 10.1016/j.cmet.2007.10.002. View